Liquidia’s Sales Are Growing. What Did It Pay to Keep Competing?

A growing medicine can produce an ugly income statement. It can also leave its owner with less commercial freedom than the sales trajectory suggests.

Liquidia reported third-quarter YUTREPIA net product sales of $222.7 million, up 31% sequentially, alongside a GAAP net loss of $236.3 million. A $389.7 million litigation settlement charge explains much of the apparent contradiction. Company-adjusted EBITDA was positive $140.5 million. Those figures are compatible; none, alone, establishes the value of the business. [1]

The investor’s task is to connect sales to the rights that support them, then follow the cash through the obligations attached to those rights.

A settlement preserves a business, with a narrower commercial scope

The settlement was signed on October 13, not announced as a new deal on November 10. Its immediate backdrop was the September 30 ruling that Liquidia infringed claims 1 and 14 of United Therapeutics’ ’327 patent concerning inhaled treprostinil treatment of pulmonary hypertension associated with interstitial lung disease, or PH-ILD. The other asserted claims were found invalid. The remedy was then unresolved, with United Therapeutics seeking restrictions on product availability. [2]

Liquidia agreed not to appeal. Its settlement resolves the six pending disputes between the companies and preserves continued commercialization of YUTREPIA for pulmonary arterial hypertension, or PAH. Liquidia has sought FDA approval to remove PH-ILD from the label and ceased promoting that use. The filing describes a submitted label supplement; that is not evidence that FDA has already approved the amended label. [3,4]

The practical restrictions extend beyond advertising. The agreement requires PAH certification in referral and prescription processes, letters requesting that specified payers deny PH-ILD prior authorizations, and letters advising clinicians to transition PH-ILD patients to alternative therapy. It also restricts the PH-ILD cohorts of the ASCENT study and dissemination of their data. These are contractual commercial and development constraints, not a new FDA determination that the medicine lacks efficacy. [3,5]

Continuity of treatment therefore cannot be translated into preservation of the entire PH-ILD opportunity. Nor does the agreement grant Liquidia a license to United Therapeutics’ patents or immunize future products and indications from litigation. [4,5]

Our interpretation is that the settlement exchanges a potentially more disruptive legal outcome for a defined payment burden and a more constrained business. Whether that exchange creates value depends on the cash the retained opportunity can generate. It cannot be settled by labeling the agreement simply favorable or unfavorable.

An expense is not a payment schedule

The agreed cash flows have several recipients. Liquidia owes United Therapeutics $330.4 million; United Therapeutics owes Liquidia $10 million for the RareGen dispute. Related agreements add approximately $60.3 million payable to parties with interests in that litigation. The rounded net cash obligation is therefore $380.7 million—not $380.7 million all paid to United Therapeutics. [3,4]

The accounting charge is approximately $389.7 million. Its difference from cash reflects asset impairments and other noncash entries, while some cash payments settle a previously recorded litigation-financing liability. It is inaccurate to treat the charge as the amount that left the bank during Q3. [4, Note 14]

It would be equally misleading to remove the charge from the investment analysis because it is unusual. A cost need not recur every quarter to reduce the cash available to shareholders. Adjusted EBITDA can help examine operations, but it excludes settlement costs and other items; it is neither operating cash flow nor cash available for distribution. [1]

The date on the cash balance matters

Liquidia’s $396.1 million cash and equivalents balance was measured on September 30, before the settlement payments. It is not a current, freely deployable reserve. [1]

The 10-Q supplies the next steps in the bridge. During October, gross payments under the settlement and related agreements totaled $245.25 million, while Liquidia received $10 million from United Therapeutics. That is approximately $235.25 million net paid. Another $145.4 million remains payable in two $72.7 million installments in 2027. The agreement specifies January 31 and April 30, with a next-business-day provision when necessary. [4, Notes 14 and 16; 5, Section 2.2]

There is a further liquidity constraint: as of October 23, $105.4 million was legally restricted as partial cash collateral for letters of credit supporting the remaining payments. The HCR financing amendment also raised the minimum cash covenant from $15 million to $45 million. [4, Notes 11 and 16]

These facts should change how a model handles liquidity, not encourage repeated subtraction of the same obligation. The collateral supports the existing settlement debt; it is not an additional settlement cost on top of the $145.4 million. A minimum-cash covenant is a constraint, not another immediate payment. And subtracting October payments from September cash does not reconstruct today’s balance: operating receipts, spending and other financing cash flows continue in the meantime.

The relevant question is how much unrestricted liquidity remains at each point in the payment calendar, after ongoing obligations, while retaining enough capacity to fund development. Management expects existing resources and continuing sales to support the plan. That expectation still depends on collections and future operations. [4]

Rebuild the forecast around the retained opportunity

The earnings release says more than 60% of referrals from launch through September included a PAH diagnosis, rising above 70% in September. These are referral figures, not a disclosed allocation of revenue by indication. A referral must still become treatment, paid demand and collected cash. [1]

Accordingly, we would not apply those percentages mechanically to Q3 revenue or annualize the quarter without adjustment. A useful forecast needs a bridge from eligible PAH referrals to patient starts, persistence, net revenue and collections, alongside the effect of PH-ILD transitions. Development spending and financing obligations then determine how much cash the operating franchise actually leaves available.

The investment case would strengthen if the retained PAH business generated durable collections while the scheduled payments were completed without compromising productive development. It would weaken if treatment transitions, net pricing, patient persistence or spending left less unrestricted liquidity than expected. These are analytical conditions, not outcomes the current disclosures have established.

The settlement has made several costs and boundaries more explicit. The next task is to test the economics within those boundaries. The decisive evidence will be post-settlement demand and cash generation—not a return to the profitability that appears after one large charge is excluded.

Sources and scope

[1] Liquidia, November 10, 2026: Third Quarter 2026 Financial Results; financial results and non-GAAP reconciliation, with commercial metrics through October where specified. Liquidia Q3 2026 results

[2] Liquidia, September 30, 2026: update on the ’327 patent ruling and unresolved remedies. Liquidia September 30 patent update

[3] United Therapeutics, Form 8-K filed October 14, 2026, reporting the October 13 settlement: payment terms, operational restrictions and covered disputes. United Therapeutics settlement 8-K

[4] Liquidia, Form 10-Q for the quarter ended September 30, 2026, filed November 10; especially Notes 11, 14 and 16: accounting reconciliation, payments, cash collateral and financing covenant. Liquidia Q3 2026 Form 10-Q

[5] Executed settlement agreement dated October 13, 2026, filed by United Therapeutics as Exhibit 99.1; particularly Sections 2–5. Executed settlement agreement

This note distinguishes company disclosures and contractual terms from our analytical interpretation. It does not make a buy, sell or hold recommendation, assign a price target, or validate the platform’s automatically generated BioScore.